Physiological and Pharmacological Regulation of the STAT3 Pathway in Cancer
MetadataShow full item record
CitationXiang, Michael. 2013. Physiological and Pharmacological Regulation of the STAT3 Pathway in Cancer. Doctoral dissertation, Harvard University.
AbstractSTAT3 is a critical oncogenic transcription factor, but how it becomes aberrantly activated in cancer is unclear. We have discovered a new pathway whose loss is associated with persistent STAT3 activation in human cancer. We found that the tumor suppressor miR-146b is a direct STAT3 target gene in normal breast epithelial cells. However, STAT regulation of miR-146b is subverted in tumor cells and is suppressed by promoter methylation, which is increased in primary breast cancers. Moreover, we show that miR-146b inhibits NF-κB-dependent IL-6 production, IL-6-dependent STAT3 activation, and IL-6/STAT3-driven functional phenotypes, thereby establishing a negative feedback loop. In addition, miR-146b expression appears to be deregulated in tumors with the highest levels of activated STAT3, and is positively correlated with patient survival. Our results indicate a new mechanism of crosstalk between STAT3 and NF-κB relevant to constitutive STAT3 activation in malignancy and the role of inflammation in oncogenesis.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:11181218
- FAS Theses and Dissertations